本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

NLS Pharmaceutics Ltd.

1.47
+0.04002.80%
成交量:4.73万
成交额:7.05万
市值:172.27万
市盈率:-0.22
高:1.53
开:1.44
低:1.44
收:1.43
数据加载中...
2024/11/04

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2024/10/15

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/08/27

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2024/06/25

SEC问询函

Form CORRESP - Correspondence
2024/05/30

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2024/05/16

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/03/27

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/12

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/05/05

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/24

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/01/18

SEC问询函

CORRESP [Cover] - Correspondence
2023/01/03

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/12/16

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/12/13

SEC问询函

CORRESP [Cover] - Correspondence
2022/06/17

SEC问询函

CORRESP [Cover] - Correspondence
2022/06/10

招股说明书

F-1 - Registration statement for certain foreign private issuers
2022/03/24

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]